Yipinhong Pharmacy

What Yipinhong Pharmacy does

Yipinhong Pharmacy (Yipinhong Pharmaceutical Group Co., Ltd., SZSE: 300723) is a Guangzhou-based, publicly traded Chinese pharmaceutical company founded in 2002 that develops, manufactures, and commercializes pediatric medications, chronic disease drugs, and other pharmaceutical products. The company operates a platform-plus-products model with three dedicated technology platforms — pediatric drugs, chronic disease innovation, and biological vaccines — supported by approximately 2,000 employees, including 400+ R&D personnel managing 108 pipeline projects and 187 drug registrations across 30 pediatric and 63 chronic disease filings.

Its most strategically significant asset is AR882 (lesinurad replacement), a next-generation selective URAT1 inhibitor for gout and tophaceous gout co-developed with US-based Arthrosi Therapeutics; AR882 has completed enrollment in two global pivotal Phase III trials, received FDA Fast Track Designation, and represents the first oral drug clinically demonstrated to dissolve existing tophi. The company's secondary innovation bet is APH01727, a once-daily oral small-molecule GLP-1 receptor agonist for Type 2 diabetes and obesity that has secured clinical trial approvals in both China and the US. Manufacturing infrastructure includes the Lianrui Smart Manufacturing Base in Guangzhou Nansha (220,000 sqm, with black-light factory automation) and the Ruishi Innovation API Base in Shaoguan Wengyuan (110 mu, FDA/EU GMP-standard).

The business model combines generic drug manufacturing revenue (driven by national medical insurance inclusion and centralized procurement wins), branded OTC sales through hospital, pharmacy, and e-commerce channels (JD, Tmall), innovation drug licensing royalties from the Arthrosi partnership (including 100% China rights and prioritized global supply rights for AR882), and CDMO services from its GMP-certified API base. R&D intensity was approximately 22.4% of revenue in 2024. The company's investment in Arthrosi (approximately 24.05% stake acquired for approximately USD 35 million) stands to benefit from Sobi's pending USD 1.5 billion acquisition of Arthrosi announced in late 2025.

Name

Yipinhong Pharmacy

Legal name

一品红药业集团股份有限公司

Website

https://apichope.com

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Yipinhong Pharmacy is a Guangzhou-based public Chinese pharmaceutical company that develops, manufactures, and commercializes pediatric and chronic disease drugs, with a pipeline anchored by AR882 (gout) and APH01727 (oral GLP-1 for diabetes/obesity) and a fully integrated API-to-commercial manufacturing footprint.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

akta.pro secondary industries

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH), Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Pharmaceutical manufacturing
• Pediatric medications
• Chronic disease drugs
• Innovative drug development
• Generic pharmaceuticals

Headquarters

HQ city

Guangzhou

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. 医药制造与销售: 一品红主要通过医药制造和销售业务获取收入，产品涵盖儿童药、慢病药等多个治疗领域。公司拥有187个药品注册批件，产品通过医院、药店、电商等多渠道销售。2023年研发投入约30,136.76万元，占营业收入比例较高，体现了对创新研发的持续投入。公司已上市产品包括芩香清解口服液、馥感啉口服液、苯磺酸氨氯地平干混悬剂、非诺贝特酸胆碱缓释胶囊等多个独家品种和首仿产品。
2. 创新药权益分成: 通过参股公司Arthrosi合作开发AR882，一品红获得了该药在中国市场100%的市场权益，以及优先为全球市场供应AR882的权益。随着AR882临床进展和上市推进，公司将从中国市场开发和全球供应链参与中获取收益。2025年Arthrosi被Sobi收购，一品红凭借早期协议锁定了关键权益。
3. 技术转化与CDMO服务: 瑞石创新原料药基地按照国际标准建设，具备大规模仿制药、创新药原料药供应生产能力，可为全球客户提供原料药CDMO服务。公司还与广州实验室、生物岛实验室等共建创新药技术产业转化中心，提供技术转化服务。

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Yipinhong is a publicly listed pharmaceutical company that develops, manufactures, and sells pediatric medications, chronic disease drugs, and innovative therapeutics through three technology platforms (pediatric drug, chronic disease innovation, biological vaccine) and two GMP-certified smart manufacturing bases. Its product portfolio spans 187 drug registrations including exclusive pediatric formulations, generic drugs passing national consistency evaluation, and proprietary innovative molecules (AR882 for gout, APH01727 for diabetes/obesity) sold via hospital channels, pharmacies, and e-commerce.

Product overview

Yipinhong Pharmacy (一品红药业集团股份有限公司, stock code: 300723) is an innovation-driven biopharmaceutical company that operates a platform-plus-products business model. The company focuses on three core therapeutic areas: pediatric medications (儿童药), chronic disease medications (慢病药), and other pharmaceutical products. The product portfolio spans multiple therapeutic categories including respiratory medications (馥感啉口服液, 益气健脾口服液, 羧甲司坦口服溶液, 银黄口服液, 熊胆川贝口服液), injectable medications (注射用阿昔洛韦, 注射用促肝细胞生长素, 注射用己酮可可碱), and traditional Chinese medicine preparations (复方香薷水). In the chronic disease space, the company has developed innovative drugs including 氘泊替诺雷（AR882）for gout treatment and APH01727片 for diabetes and weight management. Yipinhong operates dedicated technology platforms for pediatric drug development and chronic disease innovation, supported by intelligent manufacturing capabilities including the Lianrui Smart Manufacturing Base (联瑞制药) and Ruishi Innovation API Base (瑞石创新原料药基地). The company employs approximately 400+ R&D personnel and maintains continuous new product launches with over 10 new drug approvals annually, ranking first in Guangdong Province.

Differentiator

Problem solved

Functional benefit

Brands

• 联瑞制药: Smart pharmaceutical manufacturing subsidiary based in Nansha Bio-Island
• 瑞石制药
• 舒速达
• 坦络定

Products and services

• Fuganlin Oral Liquid (馥感啉口服液) Exclusive pediatric specialty drug and national TCM protected variety that clears heat and detoxifies, relieves cough and asthma, and benefits qi. Used for treating fever, cough, asthma, and sore throat in children with qi-deficiency colds. Directly inhibits viruses and modulates immune response through dual pathways.
• Yiqi Jianspi Oral Liquid (益气健脾口服液) TCM preparation that strengthens the spleen, benefits qi, and harmonizes the stomach. Used as adjunctive treatment for spleen-stomach weakness syndrome, addressing symptoms such as poor appetite, post-meal abdominal distension, and fatigue.
• Carbocisteine Oral Solution (羧甲司坦口服溶液) National Medical Insurance Category B pediatric specialty medication used for treating phlegm viscosity and cough difficulty in patients with chronic bronchitis and related conditions. The mucoregulator reduces sputum viscosity to facilitate expectoration.
• Acyclovir for Injection (注射用阿昔洛韦) Antiviral injection used for the treatment of herpes simplex virus infections, shingles, and chickenpox in immunocompromised patients.
• Hepatocyte Growth Factor for Injection (注射用促肝细胞生长素) Liver-protecting injection used as adjunctive treatment for various severe viral hepatitis conditions (acute, subacute, and chronic severe hepatitis in early or mid-stage).
• Pentoxifylline for Injection (注射用己酮可可碱) Vasodilator injection used for treatment of peripheral arterial disease (intermittent claudication or rest pain) and inner ear circulation disorders.
• Compound Xiangru Water (复方香薷水) TCM preparation that releases the exterior, transforms dampness, and harmonizes the stomach. Used for external wind-cold with internal summer-dampness causing cold-heat headache, abdominal distension and pain, nausea, and intestinal diarrhea.
• Yinhuang Oral Liquid (银黄口服液) TCM preparation that clears heat, disperses wind, benefits the throat, and detoxifies. Used for wind-heat external contractions, sore throat, throat swelling, thirst, fever, and acute/chronic tonsillitis and pharyngitis.
• Xiongdan Chuanbei Oral Liquid (熊胆川贝口服液) TCM preparation that clears heat, transforms phlegm, and relieves cough. Used for heat-phlegm cough with persistent expectoration and difficulty expectorating.
• Lesinurad Replacement (AR882) (氘泊替诺雷) Next-generation highly selective URAT1 inhibitor for gout and tophaceous gout treatment. It precisely inhibits renal uric acid reabsorption via deuterium chemistry modification, achieving long-term stable uric acid reduction. Compared to existing therapies, it strongly reduces uric acid, dissolves gout tophi, and has no renal toxicity. It is the first oral drug clinically proven to dissolve gout tophi and has entered global multi-center Phase III clinical trials.
• APH01727 Tablets Proprietary highly active and highly selective glucagon-like peptide-1 receptor agonist (GLP-1RA) targeting once-daily oral small-molecule GLP-1R agonist for type 2 diabetes treatment and weight management in overweight/obese patients. Currently no oral small-molecule GLP-1RA drug is marketed globally.
• Oseltamivir Phosphate Capsules (磷酸奥司他韦胶囊) National Medical Insurance Category B product and national essential medicine. Antiviral medication for influenza treatment and prevention in adults and children aged 1+ (treatment) and 13+ (prevention).
• Amlodipine Besylate Dry Suspension (苯磺酸氨氯地平干混悬剂) National Category 2.2 new drug and first domestically developed CCB-class oral suspension antihypertensive medication. Used for hypertension and coronary heart disease in children, adolescents, and elderly patients. Listed in Second Batch of Recommended Pediatric Drug Development Catalog and WHO Adult Hypertension Treatment Guidelines as recommended first-line antihypertensive.
• Shusuda (舒速达) Fenofibrate Choline Sustained-Release Capsules Brand-name fenofibrate choline sustained-release capsules. A statin-class lipid regulator that inhibits the production of very low-density lipoprotein cholesterol and triglycerides while increasing high-density lipoprotein cholesterol. Included in the National Medical Insurance Catalog.
• Olmesartan Medoxomil Orally Disintegrating Tablets (奥美沙坦酯口崩片) - Tanluoding (坦络定) Olmesartan medoxomil orally disintegrating tablets, first domestic manufacturer approved product with consistency evaluation for hypertension treatment. Brand name: Tanluoding (坦络定).
• Perindopril Amlodipine Tablets (II) (培哚普利氨氯地平片(II)) National Medical Insurance Category B product, registered as chemical drug category 4, deemed equivalent to passed consistency evaluation. Combination antihypertensive medication containing perindopril and amlodipine. First domestic manufacturer to receive approval through consistency evaluation.
• Mecobalamin Injection (甲钴胺注射液) National Medical Insurance Category B product, registered as chemical drug category 4, deemed equivalent to passed consistency evaluation. Mecobalamin injection for peripheral neuropathy treatment.
• Amlodipine Besylate Tablets (苯磺酸氨氯地平片) National Medical Insurance Category A product and national essential medicine (5mg), registered as chemical drug category 4, deemed equivalent to passed consistency evaluation. Antihypertensive medication.
• Aminocaproic Acid Injection (氨基己酸注射液) National Medical Insurance Category B product, deemed equivalent to passed consistency evaluation. Aminocaproic acid injection used as antifibrinolytic for bleeding control.
• Phloroglucinol Injection (间苯三酚注射液) National Medical Insurance Category B product, registered as chemical drug category 4, deemed equivalent to passed consistency evaluation. Indicated for digestive and biliary dysfunction, acute spasmodic pain, and gynecological spasmodic pain.
• Micafungin Sodium for Injection (注射用米卡芬净钠) National Medical Insurance Category B product, registered as chemical drug category 4, deemed equivalent to passed consistency evaluation. Micafungin sodium injection for antifungal treatment.
• Escitalopram Oxalate Drops (草酸艾司西酞普兰滴剂) Registered as chemical drug category 3, deemed equivalent to passed consistency evaluation. Escitalopram oxalate oral drops for depression and anxiety disorder treatment.
• Cetylpyridinium Chloride Injection (西吡氯铵注射液) Registered as chemical drug category 3, deemed equivalent to passed consistency evaluation. Cetylpyridinium chloride injection.
• Compound Polyethylene Glycol Electrolyte Powder (II) (复方聚乙二醇电解质散II) National Medical Insurance Category B product, registered as chemical drug category 4, deemed equivalent to passed consistency evaluation. Compound polyethylene glycol electrolyte powder for bowel preparation before colonoscopy or surgery.
• Isavuconazonium Sulfate Injection (注射用硫辛酸艾沙康嗪) National Medical Insurance Category B product, registered as chemical drug category 4, deemed equivalent to passed consistency evaluation. Antifungal injection for invasive aspergillosis and mucormycosis treatment.
• Linezolid Dry Suspension (利奈唑胺干混悬剂) Registered as chemical drug category 3, deemed equivalent to passed consistency evaluation. Linezolid dry suspension for treating infections caused by susceptible gram-positive bacteria.
• Oxcarbazepine Oral Suspension (奥卡西平口服混悬液) Registered as chemical drug category 4, deemed equivalent to passed consistency evaluation. First domestic generic oxcarbazepine oral suspension for epilepsy treatment.
• Procaterol Hydrochloride Oral Solution (盐酸丙卡特罗口服溶液) National Medical Insurance Category B product approved for marketing. Procaterol hydrochloride oral solution is a long-acting beta-2 agonist bronchodilator for treatment of bronchial asthma and related respiratory conditions.

Quantifiable outcome

• AR882治疗6周时75mg剂量相对非布司他体现优效(P<0.001)，75mg组86%和64%的患者达到sUA<6 mg/dL和<5mg/dL水平
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Twelve partnerships are on record, tiered 核心, 重要 and 一般.

• Sobi (Swedish Orphan Biovitrum AB)核心Strategic or Co-development Partner · 14 December 2025Arthrosi收到Sobi美国发出的收购协议，Sobi美国拟以9.5亿美元首付款及最高5.5亿美元里程碑付款收购Arthrosi 100%股权，总价值15亿美元。一品红凭借早期协议锁定了AR882在中国100%的市场权益及优先全球生产供应权。
• 中国医药企业管理协会、中国非处方药物协会重要GTM or Marketing Partner · 18 May 2025一品红协办第45届中国医药产业发展大会，并承办'创新驱动，数智领航'主题论坛，李捍雄董事长发表主题演讲。
• 以岭药业重要Strategic or Co-development Partner · 13 November 2024一品红参股企业杭州畅溪制药与以岭药业就肺部及相关疾病治疗领域的创新药研发达成战略合作，畅溪制药将利用自身在吸入粉雾剂开发领域的经验和技术，支持以岭药业创新药物分子的开发。
• 中国生物工程学会等17家国家级学协会重要GTM or Marketing Partner · 19 September 2024一品红协办第十六届中国生物产业大会，董事长李捍雄受邀出席大会并向参展领导专家作专项汇报，重点阐述公司全球创新战略布局与转化成果。
• 中国药科大学一般Strategic or Co-development Partner · 20 November 2023中国药科大学校长郝海平一行参访一品红，双方就深化校企合作、高效务实推进创新药项目落地、及中国医药专业人才培养等进行了深入交流。
• 广东省药品质量研究所一般Implementation/ SI/ Consulting Partner · 11 January 2023一品红与广东省药品质量研究所合作共建产研检平台，开展药品监管科学研究，为产业安全和创新发展提供新工具、新标准和新方法。
• 生物岛实验室重要Strategic or Co-development Partner · 26 April 2022一品红控股子公司华南疫苗与生物岛实验室合作共建粤港澳大湾区创新疫苗技术产业转化中心，由徐涛院士担任第一任理事长指导工作。
• 广州实验室重要Strategic or Co-development Partner · 28 December 2021广州实验室与一品红签约创新药成果转化战略合作框架项目，共建创新药技术产业转化中心，聚焦创新药研发和产业化。
• Lyndra Therapeutics一般Strategic or Co-development Partner · 15 October 2021一品红参股全球领先的创新药研发公司Lyndra Therapeutics，合作研发超长效缓释口服制剂，拓展首创药及新靶点创新类项目业务。
• Arthrosi Therapeutics核心Strategic or Co-development Partner · 27 July 2021一品红通过全资子公司投资3.83亿与Arthrosi达成战略合作，获得AR882和AR035项目在中国区域的研发、上市、生产、销售等全部商业化权益。一品红持有合资公司广州瑞安博医药科技有限公司60.7%股权。2024年7月追加投资1000万美元受让Arthrosi 24.05%股权，进一步提升对AR882的国内市场权益。
• 中国宋庆龄基金会重要GTM or Marketing Partner · 1 January 2020一品红联合中国宋庆龄基金会设立'中国宋庆龄基金会一品红儿童健康爱心专项基金'，用于支持儿科学术研究及公益活动的开展，支持儿童疾病科研研究，完善青少年儿童健康服务体系。
• 国药控股重要Channel Partner/ Reseller/ Distributor国药控股全球采购与供应链服务中心携33家国控省级平台公司的主要领导到访一品红参观交流，进一步巩固并深化双方合作，共同探索企业合作发展的新篇章。

Scale indicators20 records

Recent moves11 records

Expansion highlights5 records

Broad incumbents

• Shanghai Pharmaceuticals Holding: One of China's largest pharmaceutical conglomerates with comprehensive manufacturing, R&D, and distribution operations. Comparable as a broader Chinese pharma incumbent with full industry chain (manufacturing-distribution-retail) similar to Yipinhong's vertically integrated model.
• China Resources Pharmaceutical Group: Major state-owned Chinese pharmaceutical conglomerate with extensive drug manufacturing, R&D, and healthcare services. Comparable as a broader industry incumbent with full pharma value chain integration similar to Yipinhong's smart manufacturing + R&D strategy.

Direct peers

• Kexing Biopharm: Shenzhen-listed Chinese biopharmaceutical company with focus on pediatric drugs, antiviral therapies, and chronic disease treatments. Highly comparable to Yipinhong given similar pediatric and infectious disease focus, innovation pipeline, and Shenzhen exchange listing.
• Innovent Biologics: Hong Kong-listed Chinese biopharma focused on innovative biologics and small molecules in oncology and chronic diseases. Comparable as a Chinese innovative pharma with strong R&D pipeline and international partnerships (similar to Yipinhong's Arthrosi/Sobi connection).
• Tonghua Dongbao: Chinese pharmaceutical company specializing in diabetes treatment, particularly insulin products. Directly comparable to Yipinhong's metabolic disease focus (APH01727 GLP-1RA), Chinese listing, and ambition to expand from traditional products to innovative diabetes therapies.
• Livzon Pharmaceutical Group: Major Chinese pharmaceutical company with diversified portfolio including pediatric drugs, anti-infectives, and reproductive health. Comparable to Yipinhong in pediatric medicine focus, multi-platform strategy, and presence in both generics and innovative drugs.
• Hengrui Medicine: China's largest innovative pharmaceutical company with broad pipeline across oncology, anesthesia, and chronic diseases. Directly comparable to Yipinhong as a Chinese-listed innovator with significant R&D investment, multi-therapeutic platform strategy, and global partnership ambitions.
• Salubris Pharmaceuticals: Shenzhen-listed Chinese pharmaceutical company with focus on cardiovascular and chronic disease innovative drugs. Comparable to Yipinhong in terms of therapeutic area overlap (hypertension/chronic disease), Chinese listing structure, and innovation-driven strategy.

Emerging players

• BeiGene: Global biopharmaceutical company with strong China presence developing innovative oncology and immunology drugs. Comparable as an emerging Chinese-origin innovator with global ambitions, international partnerships, and significant R&D investment (similar model to Yipinhong's global innovation strategy).

Regional players

• Jointown Pharmaceutical Group: Major Chinese pharmaceutical distribution and supply chain company. Comparable to Yipinhong's distribution arm and commercial channel partnerships (Sinopharm, JD/Tmall) but focused primarily on distribution rather than R&D and manufacturing.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yipinhong Pharmacy